SLShanmuganathan Limalanathan

Shanmuganathan Limalanathan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shanmuganathan Limalanathan has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Jan Eritsland

    Department of Cardiology, Unit of Epidemiology and Biostatistics, Oslo University Hospital Ullevål, Oslo, Norway; Center for Heart Failure Research, Oslo, Norway

    4 shared publications
  • Michael Abdelnoor

    Center for Clinical Research, Unit of Epidemiology and Biostatistics, Oslo University Hospital Ullevål, Oslo, Norway

    3 shared publications
  • Nils-Einar Kløw

    Department of Radiology, Unit of Epidemiology and Biostatistics, Oslo University Hospital Ullevål, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway

    3 shared publications
  • Geir Øystein Andersen

    Department of Cardiology, Unit of Epidemiology and Biostatistics, Oslo University Hospital Ullevål, Oslo, Norway; Center for Heart Failure Research, Oslo, Norway

    2 shared publications
  • Pavel Hoffmann

    Section of Interventional Cardiology, Oslo University Hospital Ullevål, Oslo, Norway

    2 shared publications
  • Pavel Hoffmann

    Section for Interventional Cardiology, Department of Cardiology, Oslo University Hospital Ullevål, Oslo, Norway

    2 shared publications

Latest Publications

  • Open Access

    Effect of Ischemic Postconditioning on Infarct Size in Patients With ST‐Elevation Myocardial Infarction Treated by Primary PCI Results of the POSTEMI (POstconditioning in ST‐Elevation Myocardial Infarction) Randomized Trial

    by Shanmuganathan Limalanathan, Geir Ø. Andersen, Nils‐Einar Kløw, Michael Abdelnoor, Pavel Hoffmann, Jan Eritsland

    Background: Reduction of infarct size by ischemic postconditioning (IPost) has been reported in smaller proof‐of‐concept clinical studies, but has not been confirmed in other smaller studies. The principle needs to be evaluated in larger groups of ST‐elevation myocardial infarction (STEMI) patients before being implemented in clinical practice. This study assessed the effect of ischemic postcoditioning (IPost) on infarct size in patients with STEMI treated by primary percutaneous coronary intervention (PCI). Methods and Results: Patients with first‐time STEMI, P =0.18). No significant impact of IPost was found when controlling for baseline risk factors of infarct size in a multivariate linear regression model ( P =0.16). The effects of IPost on secondary endpoints, including markers of necrosis, myocardial salvage, and ejection fraction, as well as adverse cardiac events during follow‐up, were consistently neutral. Conclusions: In contrast to several smaller trials reported previously, we found no significant effects of IPost on infarct size or secondary study outcomes. Clinical Trial Registration: URL: http://www.clinicaltrials.gov Unique identifier: NCT.No.PO1506.


  • Open Access

    Myocardial Salvage is Reduced in Primary PCI-Treated STEMI Patients with Microvascular Obstruction, Demonstrated by Early and Late CMR

    by Shanmuganathan Limalanathan, Jan Eritsland, Geir Øystein Andersen, Nils-Einar Kløw, Michael Abdelnoor, Pavel Hoffmann

    This study evaluates the association between microvascular obstruction and myocardial salvage, determined by cardiac magnetic resonance performed both in the acute stage of myocardial infarction and after 4 months. In patients with acute ST-elevation myocardial infarction treated by primary percutaneous coronary intervention, myocardial salvage, infarct size, left ventricular volumes, and ejection fraction were assessed by early (1–4 days) and follow-up (4 months) cardiac magnetic resonance. These variables were related to the presence or absence of microvascular obstruction at early investigation. Myocardial salvage was determined by: (1) myocardium at risk and infarct size measured in the acute stage and (2) myocardium at risk, measured acutely, and infarct size measured after 4 months. Multivariate analyses were performed, adjusting for clinical confounders at baseline. Microvascular obstruction was present in 49 of 94 included patients, (52%). Myocardial salvage was significantly reduced in patients with microvascular obstruction, compared to those without: 23% vs. 38%, measured acutely, and 39.8% vs. 65.4%, after 4 months (p<0.001). The presence of microvascular obstruction was significantly and independently associated with large infarct size, lower left ventricular ejection fraction, and larger left ventricular end-systolic volume. The presence of microvascular obstruction demonstrated by cardiac magnetic resonance early after infarction was associated with impaired myocardial salvage. This association was more marked when based on measurement of infarct size after 4 months compared to assessment in the acute stage.


  • Rationale and Design of the POSTEMI (Postconditioning in ST-Elevation Myocardial Infarction) Study

    by Shanmuganathan Limalanathan, Geir Øystein Andersen, Pavel Hoffmann, Nils-Einar Kløw, Michael Abdelnoor, Jan Eritsland

    Rapid reperfusion of the infarct-related coronary artery is essential in the treatment of acute ST-elevation myocardial infarction (STEMI). Paradoxically, restoration of the blood flow to the ischemic area may result in further injury to the myocardium. This phenomenon is described as ‘ischemia/reperfusion injury’ and the pathophysiological mechanisms are not fully elucidated. A cardioprotective effect of ischemic postconditioning (short repetitive cycles of reperfusion and re-occlusion) has been demonstrated in experimental studies and in pilot studies on patients with acute STEMI treated with primary percutaneous coronary intervention. We present the study design of the Postconditioning in ST-Elevation Myocardial Infarction (POSTEMI) study, which is a prospective, randomized, open-label clinical trial with blinded endpoint evaluation designed to evaluate the effect of postconditioning on final infarct size. Patients with acute STEMI with symptoms of less than 6 h and proximal or mid-coronary artery occlusion will be included. The primary endpoint is infarct size, assessed by cardiac MRI after 4 months. The secondary endpoints are to evaluate the effect of postconditioning on TIMI myocardial perfusion grade, resolution of ST-segment elevation, release of markers of ischemia, left ventricular function and final infarct size related to the area at risk. A total of 260 patients will be included in the study.